SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 2026-08-14 | Option exercise | 32710 | $2.6M |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 2026-08-14 | Open-market sell | 32710 | $8.2M |
| AUSTIN ROXANNE S | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| BURNSIDE WILLIAM H.L. | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| Davis Jennifer L. | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| FALK THOMAS J | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| FREYMAN THOMAS C | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| Hart Brett J | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| MEYER MELODY B | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| Quaggin Susan E | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| RAPP EDWARD J | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| Roberts Rebecca B | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| WADDELL FREDERICK H | Director | 2026-05-08 | Grant/award | 1118 | $0 |
| Purdue David Ryan | SVP, Controller | 2026-03-04 | Open-market sell | 5230 | $1.2M |
| Siatis Perry C | EVP, GC AND SECRETARY | 2026-03-02 | Open-market sell 10b5-1 | 5777 | $1.3M |
| Siatis Perry C | EVP, GC AND SECRETARY | 2026-03-02 | Open-market sell 10b5-1 | 10291 | $2.4M |
| Siatis Perry C | EVP, GC AND SECRETARY | 2026-03-02 | Open-market sell 10b5-1 | 2600 | $612K |
| Crum Demetris D | EVP, CHIEF HR OFFICER | 2026-02-27 | Tax withholding | 1594 | $370K |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 2026-02-27 | Tax withholding | 12874 | $3.0M |
| Michael Robert A. | CHAIRMAN OF THE BOARD AND CEO, Director | 2026-02-27 | Tax withholding | 36523 | $8.5M |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Regulatory and pricing-channel risks expanded materially, with new disclosures on 340B exposure, Botox IRA price-setting (2028), PBM/intermediary access controls, and trade policy supply-chain risk collectively shifting the forward risk profile. The Humira concentration reduction is a realized outcome of biosimilar erosion already in the numbers, not a resolved risk, and provides limited offset. The net picture is a meaningful worsening concentrated in regulatory compliance and market access themes.
3 company-specific · 1 eased/removed · 1 common-mode
New disclosure of material PBM/intermediary pricing and access control risk. Identifies specific mechanisms (formulary exclusions, step therapy, rebates) that could reduce revenues and shift market share to competitors.
Pharmacy benefit managers and other supply chain intermediaries exert significant influence over pricing and patient access to our products, which could adversely affect our revenues and results of…
New disclosure of 340B program risks: growth in discounted sales, enforcement actions, litigation exposure, and potential revenue impact.
20 Laws and regulations affecting government benefit programs could impose new obligations on AbbVie, require it to change its business practices, and restrict its operations. The health care…
New disclosure of Botox price-setting selection (2028), voluntary government pricing agreement with concessions, and expanded discussion of MFN/reference pricing risks and PBM consolidation impact.
AbbVie is subject to cost-containment efforts and pricing pressures that could cause a reduction in revenues and operating earnings, and changes in the terms of rebate and chargeback programs, which…
Humira removed from major products list; revenue concentration decreased from 47% to 42%. Reflects biosimilar competition impact already realized, reducing forward-looking risk.
14 Risks Related to AbbVie's Business The expiration or loss of patent protection and licenses, including the loss of exclusivity for any of our products and increased competition from generics and…
New disclosure of trade policy risk. Pharma relies on global supply chains; tariffs/restrictions could materially increase costs and disrupt operations if unmitigated.
Trade restrictions, tariffs, and other changes in global trade policy could increase costs, disrupt supply chains, and adversely affect AbbVie’s business and results of operations. AbbVie operates…
AbbVie announced the completion of its acquisition of Apogee Therapeutics for approximately $10.9 billion ($135.11 per share in cash). This is a material acquisition disclosed under Item 7.01 (Regulation FD Disclosure) via press release. The filing explicitly states "AbbVie Inc. (the "Company") issued a press release announcing the completion of its acquisition of Apogee Therapeutics, Inc." The transaction materially expands AbbVie's immunology pipeline with late-stage assets (zumilokibart and APG273) and is expected to impact 2026-2027 earnings per share.
View raw filing on EDGAR →AbbVie entered into an underwriting agreement on August 4, 2026, to issue approximately $9.93 billion in aggregate principal amount of senior notes across nine tranches with maturities ranging from 2028 to 2066. This is a material creation of direct financial obligations. The proceeds are earmarked to fund cash payment obligations for the Apogee Therapeutics acquisition and reduce a $10 billion delayed draw term loan facility, making this a significant financing event that would materially affect investor assessment of the company's capital structure and leverage.
View raw filing on EDGAR →AbbVie issued a press release on July 31, 2026 announcing second-quarter 2026 financial results, including net revenues of $16.990 billion (up 10.2% reported, 9.5% operational), diluted EPS of $2.03 GAAP and adjusted diluted EPS of $3.65 (up 22.9%), along with detailed portfolio performance metrics and updated full-year 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →AbbVie disclosed preliminary Q2 2026 financial results and updated full-year 2026 guidance under Item 2.02, including GAAP and adjusted non-GAAP diluted EPS with a $291 million acquired IPR&D and milestones expense impact. The filing provides revised adjusted diluted EPS guidance ranges for both Q2 2026 ($3.57–$3.61) and full-year 2026 ($13.91–$14.11), with supporting detail in Exhibit 99.1, which is characteristic of an earnings release disclosure.
View raw filing on EDGAR →AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the target at approximately $10.9 billion. The press release explicitly states "AbbVie will acquire all outstanding shares of Apogee" and describes this as a material acquisition that "complements AbbVie's existing immunology portfolio." This is a clear material acquisition event requiring disclosure under Item 1.01 or 2.01, disclosed here via Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →